Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Otsuka Holdings CoSTU:OS1 -3.33%88 5-Year Yield-on-Cost % is 1.77 as of Jul. 16, 2026, which is 38% below its 10-year median of 2.86. GuruFocus rates STU:OS1 with a GF Score™ of 88/100 and a GF Value™ of €45.14 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 514 Drug Manufacturers companies, Otsuka Holdings Co ranks worse than 56.42% on this metric.
Otsuka Holdings Co's yield on cost for the quarter that ended in Mar. 2026 was 1.77.
The historical rank and industry rank for Otsuka Holdings Co's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:OS1'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.68 Med: 2.86 Max: 4.16
Current: 1.77
During the past 13 years, Otsuka Holdings Co's highest Yield on Cost was 4.16. The lowest was 1.68. And the median was 2.86.
STU:OS1's 5-Year Yield-on-Cost % is ranked worse than 56.42% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs STU:OS1: 1.77
Otsuka Holdings Co (STU:OS1) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Otsuka Holdings Co 5-Year Yield-on-Cost % Related Terms
STU:OS1 vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Otsuka Holdings Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otsuka Holdings Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Otsuka Holdings Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Otsuka Holdings Co's 5-Year Yield-on-Cost % falls into.
Otsuka Holdings Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Otsuka Holdings Co (STU:OS1) has a 5-Year Yield-on-Cost % of 1.77 as of Jul. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Otsuka Holdings Co and its competitors. This is 38% below median its historical median of 2.86. Over the past decade, Otsuka Holdings Co's 5-Year Yield-on-Cost % has ranged from 1.68 to 4.16. According to the industry distribution chart, Otsuka Holdings Co ranks #290 out of 514 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is Otsuka Holdings Co's 5-Year Yield-on-Cost % too high?
Otsuka Holdings Co's current 5-Year Yield-on-Cost % of 1.77 is 38% below median its 10-year median of 2.86. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 4.16. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.30. Otsuka Holdings Co's value of 1.77 is 23% below this industry median. Based on the distribution chart, Otsuka Holdings Co ranks #290 out of 514 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Otsuka Holdings Co has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Otsuka Holdings Co's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Otsuka Holdings Co ranks #290 out of 514 companies for 5-Year Yield-on-Cost %. This places Otsuka Holdings Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.30. Otsuka Holdings Co's value of 1.77 is 23% below this benchmark. Historically, Otsuka Holdings Co's own 5-Year Yield-on-Cost % has ranged from 1.68 to 4.16 over the past decade. While the company's 10-year median is 2.86 vs. the industry median of 2.30, Otsuka Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.30, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otsuka Holdings Co's current 5-Year Yield-on-Cost % of 1.77 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Otsuka Holdings Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otsuka Holdings Co's current 5-Year Yield-on-Cost % is 1.77, which is 38% below median its own 10-year median of 2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otsuka Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Otsuka Holdings Co (STU:OS1) is currently considered Modestly Overvalued. The stock's GF Value™ is €45.14, compared to a current price of €58.00 — trading 28.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.77, which is 38% below median its 10-year median of 2.86 and 23% below the Drug Manufacturers industry median of 2.30. Otsuka Holdings Co's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Otsuka Holdings Co (STU:OS1), the current 5-Year Yield-on-Cost % is 1.77 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Otsuka Holdings Co (STU:OS1) Overvalued in 2026?
Based on GuruFocus' analysis, Otsuka Holdings Co stock appears to be overvalued.
The current stock price of €58.00 is trading 28.5% above its estimated GF Value™ of €45.14.
GuruFocus considers Otsuka Holdings Co to be Modestly Overvalued.
Key valuation signals for STU:OS1:
5-Year Yield-on-Cost %: 1.77 (38% below median its 10-year median of 2.86)
GF Value™: €45.14 vs. price of €58.00 (28.5% above fair value)
Industry Position: 23% below the Drug Manufacturers median (#290 of 514)
No single metric tells the full story. See the STU:OS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Otsuka Holdings Co Ltd is a Japan-based company that operates in pharmaceuticals, nutraceuticals, and consumer products. It operates through four reportable segments: Medical-related Business, Nutraceutical-related Business, Consumer-related Business, and Other Business. The Medical Business manufactures and sells therapeutic drugs and infusions, the Nutraceutical Business produces functional foods, beverages, and nutritional supplements, the Consumer Business offers mineral water, beverages, and foods, while the Other Business provides storage services and manufactures chemicals and analytical equipment. It generates the majority of its revenue from the medical-related business segment.
88GF Score
Get the complete analysis for STU:OS1
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OS1 has been successfully added to your 
